Overview

Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
0
Participant gender:
All
Summary
Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Treatments:
Brinzolamide
Criteria
Inclusion Criteria:

- Central serous chorioretinopathy (CSC) affecting the fovea, non-resolving after 4
months of follow-up

- Optical coherence tomography (OCT) shows foveal subretinal fluid

- Fluorescein angiography and indocyanine green confirm the diagnosis

Exclusion Criteria:

- Any other ophthalmic condition that may lead to subretinal fluid

- Choroidal neovascularization

- Myopia > -6D

- Previous treatment for CSC in the past 6 months

- Known allergy to fluorescein or indocyanin green

- Known allergy for brinzolamide

- Pregnancy, breast feeding